Compounds > 3-acetylthioisobutyric acid
Page last updated: 2024-12-07

3-acetylthioisobutyric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID118073
SCHEMBL ID342981
MeSH IDM0238427

Synonyms (52)

Synonym
SR-01000630983-1
3-acetylthioisobutyric acid
HMS1661N04
FT-0650557
inchi=1/c6h10o3s/c1-4(6(8)9)3-10-5(2)7/h4h,3h2,1-2h3,(h,8,9)
vfvhnrjeyqgrge-uhfffaoysa-
propanoic acid, 3-(acetylthio)-2-methyl-
3-acetylsulfanyl-2-methylpropanoic acid
d-(-)-3-acetylthio-2-methylpropionic acid
3-acetylthio-2-methylpropanoic acid
33325-40-5
A821726
AKOS006228965
3-(acetylsulfanyl)-2-methylpropanoic acid
unii-r696cmv409
3-(acetylthio)-2-methylpropionic acid
einecs 277-856-9
3-(acetylthio)-2-methylpropanoic acid
r696cmv409 ,
2-methyl-3-(acetylthio)propionic acid
einecs 251-458-5
3-mercapto-2-methylpropionic acid, acetate
(1)-3-(acetylthio)-2-methylpropionic acid
einecs 278-480-8
CCG-40872
FT-0641595
SCHEMBL342981
3-mercapto-2-methylpropionic acid acetate
(rs)-3-acetylthio-2-methylpropionic acid
3-acetylthio-2-methylpropionic acid
captopril impurity g [ep impurity]
3-acetylsulfanyl-2-methylpropionic acid
(+/-)-3-acetylthio-2-methylpropionic acid
propionic acid, 3-mercapto-2-methyl-, acetate
2-(acetylthiomethyl)propanoic acid
3-acetylthio 2-(rs) methylpropionic acid
3-acetylthio-2-(rs) methylpropionic acid
s-acetyl-beta-mercaptoisobutyric acid
2-methyl-3-acetylmercaptopropionic acid
3-(acetylsulfanyl)-2-methylpropanoic acid #
s-acetyl-2-methyl-3-mercaptopropionic acid
d-3-acetylsulfanyl-2-methyl propionic acid
J-019143
DTXSID90868398
(r,s)-beta-acetylmercaptoisobutyric acid
3-(acetylthio)-2-methyl-propanoic acid
1189969-31-0
3-acetylthio-2-methylpropionicacid
3-acetylsulfur-2-methylpropionic acid
Q27287849
A935853
3-mercapto-2-methylpropionic acid acetate (rs)-3-acetylthio-2-methylpropionic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (12.50)18.2507
2000's2 (25.00)29.6817
2010's4 (50.00)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.60 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
cetraxate
[no description available]		2.0110benzenes;
monocarboxylic acid
tranexamic acid
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.		2.0110amino acid
ConditionIndicatedRelationship StrengthStudiesTrials
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610
Plasmodium falciparum Malaria
[description not available]		02.110
Malaria, Falciparum
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.		02.110
Anemia, Fanconi
[description not available]		02.1310
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		02.1310